RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (AMEX: ISR), a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the third quarter of fiscal year 2010, ended March 31, 2010.
